Indivior PLC (NASDAQ:INDV) Short Interest Update

Indivior PLC (NASDAQ:INDV - Get Free Report) was the recipient of a significant decline in short interest during the month of March. As of March 31st, there was short interest totalling 2,000,000 shares, a decline of 20.9% from the March 15th total of 2,530,000 shares. Approximately 1.8% of the shares of the stock are short sold. Based on an average daily trading volume, of 1,370,000 shares, the days-to-cover ratio is presently 1.5 days.

Indivior Price Performance

NASDAQ INDV traded up $0.63 on Wednesday, hitting $9.44. 863,232 shares of the stock were exchanged, compared to its average volume of 957,832. The company's 50-day moving average price is $9.45 and its two-hundred day moving average price is $10.30. Indivior has a 52-week low of $7.33 and a 52-week high of $19.13. The company has a market capitalization of $1.30 billion, a price-to-earnings ratio of -26.96 and a beta of 0.93.

Indivior (NASDAQ:INDV - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The company reported $0.32 earnings per share for the quarter, meeting analysts' consensus estimates of $0.32. The business had revenue of $298.00 million for the quarter, compared to the consensus estimate of $262.35 million. Indivior had a negative return on equity of 241.73% and a negative net margin of 3.96%. Equities analysts predict that Indivior will post 1.22 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently commented on INDV. RODMAN&RENSHAW upgraded Indivior to a "strong-buy" rating in a research report on Tuesday, January 28th. Piper Sandler decreased their price target on Indivior from $16.00 to $13.00 and set an "overweight" rating for the company in a research report on Thursday, March 6th. Finally, Rodman & Renshaw assumed coverage on Indivior in a research note on Tuesday, January 28th. They issued a "buy" rating and a $16.00 price target on the stock.

Institutional Trading of Indivior

Hedge funds have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. purchased a new position in Indivior during the fourth quarter valued at approximately $359,000. Stifel Financial Corp purchased a new position in shares of Indivior during the 3rd quarter valued at $100,000. Hennion & Walsh Asset Management Inc. acquired a new position in shares of Indivior in the fourth quarter worth $1,192,000. Geode Capital Management LLC raised its holdings in shares of Indivior by 7.7% during the third quarter. Geode Capital Management LLC now owns 132,239 shares of the company's stock worth $1,289,000 after acquiring an additional 9,500 shares in the last quarter. Finally, VELA Investment Management LLC boosted its position in Indivior by 45.5% during the fourth quarter. VELA Investment Management LLC now owns 179,659 shares of the company's stock valued at $2,264,000 after purchasing an additional 56,224 shares during the last quarter. 60.33% of the stock is owned by hedge funds and other institutional investors.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.